Another buyout to start 2023 - Sanofi acquires diabetes drug via Provention buyout.
Cope and paste extract of the article below.
Dive Brief:French pharmaceutical company Sanofi on Monday said it will pay $2.9 billion to acquire Provention Bio, a biotechnology company that recently won U.S. approval of a new type of Type 1 diabetes drug.
Provention Bio gained an OK from the Food and Drug Administration in November for Tzield, an injectable drug that’s meant to delay the onset Type 1 diabetes.
The acquisition expands on a marketing agreement Sanofi signed with Provention back in October.Provention is the latest company to be acquired by Sanofi since 2020, when CEO Paul Hudson shifted the company’s focus toward drugs for cancer and immune diseases.
Another buyout to start 2023 - Sanofi acquires diabetes drug via...
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.22 |
Change
0.030(2.52%) |
Mkt cap ! $202.7M | |||
| Open | High | Low | Value | Volume |
| $1.22 | $1.22 | $1.16 | $78.70K | 66.45K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1000 | $1.18 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.22 | 4561 | 1 |
View Market Depth
| Last trade - 16.10pm 07/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.19 |
Change
0.030 ( 0.42 %) |
||||
| Open | High | Low | Volume | ||
| $1.19 | $1.22 | $1.16 | 11297 | ||
| Last updated 15.56pm 07/05/2024 ? | |||||
| RAC (ASX) Chart |